Model Performance Evaluation (Validation and Calibration) in Model-based Studies of Therapeutic Interventions for Cardiovascular Diseases

Decision analytic models play an increasingly important role in the economic evaluation of health technologies. Given uncertainties around the assumptions used to develop such models, several guidelines have been published to identify and assess ‘best practice’ in the model development process, including general modelling approach (e.g., time horizon), model structure, input data and model performance evaluation. This paper focuses on model performance evaluation. In the absence of a sufficient level of detail around model performance evaluation, concerns regarding the accuracy of model outputs, and hence the credibility of such models, are frequently raised. Following presentation of its components, a review of the application and reporting of model performance evaluation is presented. Taking cardiovascular disease as an illustrative example, the review investigates the use of face validity, internal validity, external validity, and cross model validity. As a part of the performance evaluation process, model calibration is also discussed and its use in applied studies investigated. The review found that the application and reporting of model performance evaluation across 81 studies of treatment for cardiovascular disease was variable. Cross-model validation was reported in 55 % of the reviewed studies, though the level of detail provided varied considerably. We found that very few studies documented other types of validity, and only 6 % of the reviewed articles reported a calibration process. Considering the above findings, we propose a comprehensive model performance evaluation framework (checklist), informed by a review of best-practice guidelines. This framework provides a basis for more accurate and consistent documentation of model performance evaluation. This will improve the peer review process and the comparability of modelling studies. Recognising the fundamental role of decision analytic models in informing public funding decisions, the proposed framework should usefully inform guidelines for preparing submissions to reimbursement bodies.

[1]  Ron Goeree,et al.  A Review of Methods Used in Long-Term Cost-Effectiveness Models of Diabetes Mellitus Treatment , 2012, PharmacoEconomics.

[2]  Using triple antiplatelet therapy in patients with non-ST elevation acute coronary syndrome managed invasively: a cost-effectiveness analysis. , 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[3]  J. Latour‐Pérez,et al.  Cost Effectiveness of Fondaparinux in Non-ST-Elevation Acute Coronary Syndrome , 2012, PharmacoEconomics.

[4]  M Sculpher,et al.  Health Technology Assessment: Development and Future , 2009 .

[5]  N. Maniadakis,et al.  Economic evaluation of treatment strategies for patients suffering acute myocardial infarction in Greece. , 2005, Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese.

[6]  Natasha K. Stout,et al.  Calibration Methods Used in Cancer Simulation Models and Suggested Reporting Guidelines , 2012, PharmacoEconomics.

[7]  Richard G. White,et al.  Calibrating Models in Economic Evaluation , 2012, PharmacoEconomics.

[8]  L. Goldman,et al.  Health and Economic Benefits of Increased β-Blocker Use Following Myocardial Infarction , 2000 .

[9]  Kristian Bolin,et al.  Economic Evaluation of Smoking-Cessation Therapies , 2012, PharmacoEconomics.

[10]  D. Owens,et al.  Cost-effectiveness of bypass surgery versus stenting in patients with multivessel coronary artery disease. , 2003, The American journal of medicine.

[11]  J Karnon,et al.  Selecting a decision model for economic evaluation: a case study and review , 1998, Health care management science.

[12]  J. Herlitz,et al.  Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (high-risk) atherosclerotic patients in Sweden , 2010, Applied health economics and health policy.

[13]  William Hollingworth,et al.  Model Transparency and Validation , 2012, Medical decision making : an international journal of the Society for Medical Decision Making.

[14]  M. Eckman,et al.  Cost-effectiveness of telemetry for hospitalized patients with low-risk chest pain. , 2011, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.

[15]  M. Ridao-López,et al.  Using clopidogrel in non-ST-segment elevation acute coronary syndrome patients: a cost-utility analysis in Spain. , 2004, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[16]  J. Brazier,et al.  Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of non-ST-segment elevation acute coronary syndromes. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[17]  L. Coupal,et al.  Estimating the Cost Effectiveness of Ramipril used for Specific Clinical Indications , 2007, American journal of cardiovascular drugs : drugs, devices, and other interventions.

[18]  Uwe Siebert,et al.  Modelling the Cost Effectiveness of Treatments for Parkinson’s Disease , 2011, PharmacoEconomics.

[19]  Anya Okhmatovskaia,et al.  Validation of population-based disease simulation models: a review of concepts and methods , 2010, BMC public health.

[20]  H. Kohli Scottish Medicines Consortium. , 2005, The National medical journal of India.

[21]  A. Smala,et al.  Clopidogrel versus aspirin in patients with atherothrombosis: CAPRIE-based calculation of cost-effectiveness for Germany , 2008, Current medical research and opinion.

[22]  Jonathan Karnon,et al.  Addressing the Challenge for Well Informed and Consistent Reimbursement Decisions , 2011, PharmacoEconomics.

[23]  P Tappenden,et al.  Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer. , 2007, Health technology assessment.

[24]  M J Buxton,et al.  Modelling in economic evaluation: an unavoidable fact of life. , 1997, Health economics.

[25]  Jonathan Karnon,et al.  A Critical Review of Model-Based Economic Studies of Depression , 2012, PharmacoEconomics.

[26]  D. Cameron,et al.  Edinburgh Research Explorer Health economics in drug development: efficient research to inform healthcare funding decisions , 2022 .

[27]  M Sculpher,et al.  A pilot study on the use of decision theory and value of information analysis as part of the NHS Health Technology Assessment programme. , 2004, Health technology assessment.

[28]  A Gafni,et al.  Systematic validation of disease models for pharmacoeconomic evaluations. Swiss HIV Cohort Study. , 1999, Journal of evaluation in clinical practice.

[29]  L. Coupal,et al.  The cost-effectiveness of exercise training for the primary and secondary prevention of cardiovascular disease. , 2000, Journal of cardiopulmonary rehabilitation.

[30]  Jonathan Karnon,et al.  Improving the Accuracy and Comparability of Model-Based Economic Evaluations of Health Technologies for Reimbursement Decisions , 2013, Medical decision making : an international journal of the Society for Medical Decision Making.

[31]  J. Homer,et al.  A system dynamics model for planning cardiovascular disease interventions. , 2010, American journal of public health.

[32]  Bartele Marten Sybrens Long-Term Clopidogrel Therapy in Patients Receiving Percutaneous Coronary Intervention , 2015 .

[33]  Milton C Weinstein,et al.  Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies. , 2003, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[34]  L. Goldman,et al.  Health and economic benefits of increased beta-blocker use following myocardial infarction. , 2000, JAMA.

[35]  Karl Claxton,et al.  Assessing Quality in Decision Analytic Cost-Effectiveness Models , 2000, PharmacoEconomics.

[36]  B. Jönsson,et al.  The cost-effectiveness of dual oral antiplatelet therapy following percutaneous coronary intervention , 2005, The European Journal of Health Economics.

[37]  C. Fidler,et al.  Enoxaparin is a cost-effective adjunct to fibrinolytic therapy for ST-elevation myocardial infarction in contemporary practice , 2010, Advances in therapy.

[38]  Sarah Wordsworth,et al.  Applied Methods of Cost-Effectiveness Analysis in Healthcare , 2010 .

[39]  Simon Dixon,et al.  Testing the Validity of Cost-Effectiveness Models , 2000, PharmacoEconomics.

[40]  Ping Zhang,et al.  Computer modeling of diabetes and its complications: a report on the Fifth Mount Hood challenge meeting. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[41]  Karen M Kuntz,et al.  Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. , 2002, The New England journal of medicine.

[42]  Milton C. Weinstein,et al.  Recent Developments in Decision-Analytic Modelling for Economic Evaluation , 2012, PharmacoEconomics.

[43]  P. Tappenden,et al.  Continuing the multiple sclerosis risk sharing scheme is unjustified , 2010, BMJ : British Medical Journal.

[44]  Paul A Scuffham,et al.  Cost-effectiveness of coronary computed tomography and cardiac stress imaging in the emergency department: a decision analytic model comparing diagnostic strategies for chest pain in patients at low risk of acute coronary syndromes. , 2011, JACC. Cardiovascular imaging.

[45]  Alan Brennan,et al.  Computer Modeling of Diabetes and Its Complications , 2007, Diabetes Care.

[46]  E Goyder,et al.  A review and critique of modelling in prioritising and designing screening programmes. , 2007, Health technology assessment.

[47]  Mark Sculpher,et al.  Is primary angioplasty cost effective in the UK? Results of a comprehensive decision analysis , 2007, Heart.

[48]  Jill M Ferdinands,et al.  Obstructive Lung Disease Models: What Is Valid? , 2008, COPD.

[49]  J Hutton,et al.  Modeling in economic evaluation: an unavoidable fact of life. , 1998, Health economics.

[50]  Simon G Thompson,et al.  Uncertainty and validation of health economic decision models. , 2009, Health economics.

[51]  J. Avorn,et al.  Cost-Effectiveness of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor Therapy in Older Patients with Myocardial Infarction , 2000, Annals of Internal Medicine.